Bristol-Myers Squibb Company (BMY)vsWheaton Precious Metals Corp (WPM)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
WPM
Wheaton Precious Metals Corp
$138.85
+5.54%
BASIC MATERIALS · Cap: $59.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 1995% more annual revenue ($48.48B vs $2.31B). WPM leads profitability with a 63.6% profit margin vs 15.0%. WPM appears more attractively valued with a PEG of 0.43. WPM earns a higher WallStSmart Score of 76/100 (B+).
BMY
Buy60
out of 100
Grade: C+
WPM
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Intrinsic value data unavailable for WPM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Growing faster than its price suggests
Keeps 64 of every $100 in revenue as profit
Strong operational efficiency at 75.2%
Revenue surging 127.2% year-over-year
Earnings expanding 533.0% YoY
Large-cap with strong market position
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : WPM
The strongest argument for WPM centers on PEG Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 63.6% and operating margin at 75.2%. Revenue growth of 127.2% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : WPM
The primary concerns for WPM are P/E Ratio. A P/E of 40.6x leaves little room for execution misses.
Key Dynamics to Monitor
BMY profiles as a value stock while WPM is a growth play — different risk/reward profiles.
WPM carries more volatility with a beta of 1.18 — expect wider price swings.
WPM is growing revenue faster at 127.2% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Bottom Line
WPM scores higher overall (76/100 vs 60/100), backed by strong 63.6% margins and 127.2% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Wheaton Precious Metals Corp
BASIC MATERIALS · GOLD · USA
Wheaton Precious Metals Corp. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?